GlassScriptPhysician profile
Jessica Mena
NPI 1396433157
$7,988.25
in general payments reported to CMS, 2019-2025
58 companies · $3,962 in 2025
The $3,962 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $383 · 2024: $3,643 · 2025: $3,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,670 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,669.66 |
| Education | $318.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $692.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $645.78 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $638.94 | 2023-2025 | Enhertu, Datroway, Calquence |
| Janssen Biotech, INC. | $535.81 | 2023-2025 | Carvykti, Erleada, Rybrevant |
| Daiichi Sankyo INC. | $433.54 | 2024-2025 | Enhertu, Datroway |
| Tempus Ai, INC | $400.79 | 2024-2025 | Xt Cdx |
| Pfizer INC. | $379.49 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $359.71 | 2023-2025 | Iclusig, Ninlaro, Alunbrig |
| Lilly USA, LLC | $339.41 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Array Biopharma INC | $234.44 | 2024-2025 | Mektovi, Braftovi, Xalkori |
| Eisai INC. | $229.17 | 2023-2025 | |
| Abbvie INC. | $221.29 | 2024-2025 | |
| Incyte Corporation | $208.04 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $175.12 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Stemline Therapeutics INC. | $164.23 | 2024-2025 | Orserdu |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.